Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Two Pharma JVs Start Operations in China: Hisun-Pfizer and Merck-Simcere

publication date: Sep 13, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Two high-visibility generic drug JVs between east and west pharmas have commenced operations in China. Hisun Pharma and Pfizer have established their $295 million JV to produce branded generic drugs. At the same time, Merck and Simcere teamed up to concentrate on generic drugs for chronic ailments, especially cardiovascular and metabolic disease. Both were announced as letters of intent just over a year ago, and now they have become operational. More details....

Stock Symbols: (SHE: 600267) (NYSE: PFE) (NYSE: MRK) (NYSE SCR)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors